DRG Category: 202
Mean LOS: 3.7 days
Description: Medical: Bronchitis and Asthma With Complication or Comorbidity or Major Complication or Comorbidity
Asthma is classified as an intermittent, reversible, obstructive disease of the lungs. It is a growing health problem in the United States, with approximately 25 million people affected. In the past 20 years, the number of children with asthma has increased markedly, and it is now the leading serious chronic illness in children. Unfortunately, approximately 75% of children with asthma continue to have chronic problems in adulthood. The total deaths annually from asthma have increased by over 100% since 1979 in the United States.
Asthma is a disease of the airways characterized by airway inflammation and hyperreactivity (increased responsiveness to a wide variety of triggers). Hyperreactivity leads to airway obstruction due to acute onset of muscle spasm in the smooth muscle of the tracheobronchial tree, thereby leading to a narrowed lumen. In addition to muscle spasm, there is swelling of the mucosa, which leads to edema. Although asthma can result from infections (especially viral) and inhaled irritants, it often is the result of an allergic response. An allergen (antigen) is introduced to the body, and sensitizing antibodies such as immunoglobulin E (IgE) are formed. IgE antibodies bind to tissue mast cells and basophils in the mucosa of the bronchioles, lung tissue, and nasopharynx. An antigen–antibody reaction releases primary mediator substances such as histamine, slow-reacting substance of anaphylaxis (SRS-A), and others. These mediators cause contraction of the smooth muscle and tissue edema. In addition, goblet cells secrete a thick mucus into the airways that causes obstruction. Intrinsic asthma results from all other causes except allergies, such as infections (especially viral), inhaled irritants, and other causes or etiologies. The parasympathetic nervous system becomes stimulated, which increases bronchomotor tone, resulting in bronchoconstriction.
In asthma, the total lung capacity (TLC), functional residual capacity (FRC), and residual volume (RV) increase, but the hallmark of airway obstruction is a reduction in ratio of the forced expiratory volume in 1 second (FEV1) to the forced vital capacity (FVC). Complications include pneumonia, atelectasis, respiratory failure with hypoxemia, and status asthmaticus (severe and refractory asthma). The classification for asthma is described in Table 1.
Table 1 Classification of Asthma
| CLASSIFICATION | DESCRIPTION |
|---|
| Mild intermittent | - Less than twice a week: Cough, wheeze, chest tightness, difficulty breathing
- Brief flare-ups with varying intensity; no symptoms between flare-ups
- Less than twice a month: Nighttime symptoms
- Lung function tests: FEV1 ≥ 80% normal values; peak flow < 20% variability a.m. to a.m. or a.m. to p.m., day to day
| | Mild persistent | - Three to six times a week: Cough, wheeze, chest tightness, difficulty breathing
- Flare-ups may affect activity level
- Three to four times a month: Nighttime symptoms
- Lung function tests: FEV1 ≥ 80% normal values; peak flow < 20%–30% variability a.m. to a.m. or a.m. to p.m., day to day
| | Moderate persistent | - Daily: Cough, wheeze, chest tightness, difficulty breathing affecting activity level; symptoms may last for days
- Flare-ups may affect activity level
- Five or more times a month: Nighttime symptoms
- Lung function tests: FEV1 > 60% but < 80% normal values; peak flow > 30% variability a.m. to a.m. or a.m. to p.m., day to day
| | Severe persistent | - Continual: Cough, wheeze, chest tightness, difficulty breathing that limits activity level
- Frequently: Nighttime symptoms
- Lung function tests: FEV1 ≤ 60% normal values; peak flow > 30% variability a.m. to a.m. or a.m. to p.m., day to day
|
|
The main triggers for asthma are allergies, viral infections, autonomic nervous system imbalances that can cause an increase in parasympathetic stimulation, medications, psychological factors, and exercise. Of asthmatic conditions in patients under 30 years old, 70% are caused by allergies. Three major indoor allergens are dust mites, cockroaches, and cats. In older patients, the cause is almost always nonallergic types of irritants, such as smog. Heredity plays a part in about one-third of the cases.
The genetic contributions to the development of asthma have been estimated at between 30% and 50% for various asthma phenotypes, and up to 70% for overall IgE levels in plasma. Familial factors thus far appear to be inherited in an autosomal dominant pattern. There are at least 11 candidate genes that contribute to asthma susceptibility. These include PTGDR, GPRA, IRAK3, CHI3L1, HNMT, ADRB2, IL13, SCGB3A2, TNF, HLA-G, and PLA2G7.
Although the incidence of asthma is estimated at 5% to 10% in the general population, children have a higher incidence of 12%. Children make up one-third of the people with asthma; in the United States, 7 million children are affected, and trends suggest an increasing incidence of asthma in children under the age of 6 years. Asthma is diagnosed more frequently in males under 14 years and over 45 years of age and in females between the ages of 15 and 45 years. Most experts agree that environmental factors play a more important role in asthma etiology than do genetic factors. Approximately 80% to 85% of childhood asthma episodes are associated with a prior exposure to a virus.
The Asthma and Allergy Foundation of America (2020) has written extensively about asthma disparities in the United States. The burden of asthma falls disproportionately on Black, Hispanic, and Native American persons. People from Puerto Rico are two times more likely than White persons to have asthma. Black persons are 1.5 times more likely than White persons to have asthma and are three times more likely to die from asthma than White persons. Black women have the highest death rate from asthma of all groups, and Black children have higher morbidity and mortality rates than White children. Disparities in asthma result from complex factors such as structural determinants (racism, discrimination), social determinants (education, income, neighborhood), biological determinants (ancestry), and behavioral determinants (tobacco use and medication adherence).
Asthma disparities also occur in gender and sexual minority persons. In a study of more than 300,000 youths, scientists found that lesbian, gay, and bisexual youths were more likely to have been diagnosed with asthma compared to heterosexual youth (Curry et al., 2020). Asthma disparities are perpetuated because sexual minority youth receive poor quality of care due to stigma, lack of healthcare providers' awareness, and insensitivity to the unique needs of this community.
Asthma prevalence varies widely across many countries, with a range from 1% to over 30% in children. Approximately 300 million people globally have asthma, and the prevalence increases by 50% every 10 years. Prevalence is high in developed countries in North America, Europe, and Australia and is increasing in developing countries as they become more industrialized. Examples include increases in South Africa, Eastern Europe, and the Baltic states. The greatest increases are seen in children. The more urbanization and affluence in a country, the higher is the prevalence.
PLANNING AND IMPLEMENTATION
Collaborative
For all but the most seriously ill patients, the primary goal is to prevent symptoms and reduce adverse events when acute episodes occur. Airway obstruction is generally managed with quick relief medications such as short-acting bronchodilators, systemic corticosteroids, and ipratropium (Atrovent). During severe exacerbations, patients may require IV fluid replacement. Unless contraindicated by a cardiac problem, 3,000 to 4,000 mL/day of fluid is usually administered intravenously, which helps loosen secretions and facilitates expectoration of the secretions. Low-flow oxygen therapy based on arterial blood gas results is often administered to treat hypoxemia. For the patient with increasing airway obstruction, endotracheal intubation and perhaps mechanical ventilation may be needed to maintain adequate airway and breathing. Close follow-up is needed when patients are discharged from the hospital because airway hyperactivity usually persists for 4 to 6 weeks after the event. To prevent symptoms, long-term control medications such as inhaled corticosteroids, inhaled cromolyn, long-acting bronchodilators, theophylline, leukotriene modifiers, and anti-IgE antibodies are used.
The National Institutes of Health (NIH, 2020) has developed a stepwise approach for managing asthma for children organized by age with preferred and alternative plans depending on asthma severity, from low to high. For example, the preferred recommendations for children 0 to 4 years of age follows: Step 1 is short-acting beta agonists (SABAs) as needed. Step 2 is low-dose inhaled corticosteroids (ICSs). Step 3 is medium-dose ICSs. Step 4 is medium-dose ICSs and either long-acting beta agonists (LABAs) or montelukast. Step 5 is high dose ICS and either LABA or montelukast. Other directions include to Step Up if needed and reassess in 2 to 6 weeks. Also Step Down if possible (if asthma is well controlled for at least 3 consecutive months). The recommendation is also to consult with an asthma specialist if step 4 or higher is required, and to consider consultation at step 3. Control assessment is a key element of asthma care, involving both impairment and risk. Use of objective measures, self-reported control, and healthcare utilization are complementary and should be employed on an ongoing basis, depending on the individual's clinical situation. NIH also recommends patient education and environmental control at each step.
| Medication or Drug Class | Dosage | Description | Rationale |
|---|
| Bronchodilators | Varies by drug | Inhaled beta2-adrenergic agonists by metered-dose inhaler (MDI); albuterol sulfate, pirbuterol acetate, levalbuterol | Reversal of airflow obstruction; relieve reversible bronchospasm by relaxing bronchial smooth muscles; used to treat bronchospasm in acute asthmatic episodes; used to prevent bronchospasm associated with exercise-induced asthma or nocturnal asthma |
| Systemic and inhaled corticosteroids | Varies by drug | Methylprednisolone IV; prednisone PO; inhaled corticosteroids (ciclesonide, beclomethasone, fluticasone, budesonide, mometasone) | Decrease inflammatory response; ideal dose is not defined well, but desired outcome is to speed recovery and limit symptoms |
| Leukotriene antagonists | Varies by drug | Montelukast 10 mg PO daily; zafirlukast 20 mg PO daily | Inhibits leukotrienes, fatty acids that mediate inflammation, from binding to airway smooth muscle cells; prevents rather than reduces symptoms; used for long-term prevention |
Other Drugs: Xanthines, such as theophylline, have been used successfully in treating chronic severe steroid-dependent asthmatics. They must be used regularly and not for sudden breathing difficulties to be most effective. Cromolyn sodium decreases bronchospasm, but it is not effective for acute bronchospasms and is used as a preventive measure.
Independent
Maintenance of airway, breathing, and circulation is the primary consideration during an acute attack. Patients should be on bedrest to minimize their oxygen consumption and to decrease the work of breathing. Note that patients usually assume a position to ease breathing; some patients breathe more easily while sitting in an upright position: Do not impose bedrest on a patient who can breathe only in another position. Ask questions that can be answered by nodding or a brief one-word answer so the patient can conserve energy for breathing. If the patient is a child, allow the parents to stay with the child during acute attacks. Have the parents identify a security item that reassures the child, such as a special blanket or toy, and keep the item with the child at all times. Reinforce coping strategies to the parents, and allow them to express any feelings of guilt and helplessness.
For strategies to prevent future attacks, discuss triggers that can induce asthma attacks and ways to avoid them. If the attack is triggered by an allergen, explore with the patient or family the source and discuss possible strategies for eliminating it. Cold air and exercise may increase symptoms. Aspirin and NSAIDs can cause sudden, severe airway obstruction.
Outline the signs and symptoms that require immediate attention. Instruct the patient to notify the physician should they develop a respiratory infection that could trigger an attack. Instruct patients regarding their medications, particularly MDIs, and the indications for use. It is important that the patient uses the bronchodilator MDIs first and then uses the steroid inhalers. Explain to patients on steroid inhalers the need to rinse their mouths out after using them to avoid getting thrush.
Evidence-Based Practice and Health Policy
Wang, L., Timmer, S., & Rosenman, K. (2020). Assessment of a university-based outpatient asthma education program for children. Journal of Pediatric Health Care, 34, 128–135.
- The purpose of this randomized intervention/control quality improvement project was to compare outcomes before and after patients and families were offered a home visit to assess environmental asthma triggers. Outcomes number included clinic and/or urgent care visits, emergency department visits, hospitalization, and spirometry results. Of 901 eligible pediatric patients, 458 were randomized to the control and 443 to the intervention groups.
- Of the 443 patients in the control group, 271 received the educational intervention. Only 27 families allowed a home visit, which consisted of education on pathophysiology, self-management techniques, modifications of triggers, and proper use of medications. The results demonstrated a decrease in acute care services after asthma education, but it is important to note only 10% of the intervention group permitted home visitations.